Despite large choice of effective therapies: Individuals with psoriasis still seem undertreated.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
23
06
2020
accepted:
01
12
2020
pubmed:
7
5
2021
medline:
19
8
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
Due to the development of new anti-psoriatic drugs in combination with improved structures for implementation throughout Germany, the medical care of psoriasis patients has markedly improved. In this study we investigated the real-life utilization of the health care system and identified reasons for dissatisfaction in affected individuals. This non-interventional cross-sectional study was conducted as an anonymous online survey from 12/2018 to 01/2019 in Germany. Participants with a self-reported physician-confirmed diagnosis of psoriasis and symptoms answered questions about their disease, its influence on daily life and their medical care. 649 participants with a mean age of 42.5 ± 13.7 years and equal gender distribution (male: 50.2 %) were evaluated. 54.1 % received medical treatment at the time of the study, 45.9 % did not. Among the participants with medical care, 59.3 % were only moderately or less satisfied with their treatment. Reasons for dissatisfaction with the medication included lack of efficacy and side effects. Participants without medical treatment specified a physician's lack of time as a main reason for not seeking medical help. Despite the availability of efficient therapeutic options in Germany, many individuals with psoriasis are not satisfied. This under-treated group was identified as a new target population.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Due to the development of new anti-psoriatic drugs in combination with improved structures for implementation throughout Germany, the medical care of psoriasis patients has markedly improved. In this study we investigated the real-life utilization of the health care system and identified reasons for dissatisfaction in affected individuals.
PATIENTS AND METHODS
METHODS
This non-interventional cross-sectional study was conducted as an anonymous online survey from 12/2018 to 01/2019 in Germany. Participants with a self-reported physician-confirmed diagnosis of psoriasis and symptoms answered questions about their disease, its influence on daily life and their medical care.
RESULTS
RESULTS
649 participants with a mean age of 42.5 ± 13.7 years and equal gender distribution (male: 50.2 %) were evaluated. 54.1 % received medical treatment at the time of the study, 45.9 % did not. Among the participants with medical care, 59.3 % were only moderately or less satisfied with their treatment. Reasons for dissatisfaction with the medication included lack of efficacy and side effects. Participants without medical treatment specified a physician's lack of time as a main reason for not seeking medical help.
CONCLUSIONS
CONCLUSIONS
Despite the availability of efficient therapeutic options in Germany, many individuals with psoriasis are not satisfied. This under-treated group was identified as a new target population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1011Informations de copyright
© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Körber A, Wilsmann-Theis D, Augustin M et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges 2019; 17 (Suppl 4): 3-14.
Augustin M, Glaeske G, Radtke MA et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-6.
Tizek L, Schielein MC, Seifert F et al. Skin diseases are more common than we think: screening results of an unreferred population at the Munich Oktoberfest. J Eur Acad Dermatol Venereol 2019; 33: 1421-8.
Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci 2020; 21(5): 1690.
Augustin M, Reich K, Glaeske G et al. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-51.
Zink A, Herrmann M, Fischer T et al. Addiction: an underestimated problem in psoriasis health care. J Eur Acad Dermatol Venereol 2017; 31: 1308-15.
Bronckers I, vanGeel MJ, van deKerkhof PCM et al. A cross-sectional study in young adults with psoriasis: potential determining factors in quality of life, life course and work productivity. J Dermatolog Treat 2019; 30: 208-15.
Gelfand JM, Feldman SR, Stern RS et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704-8.
Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
Schuster B, Ziehfreund S, Albrecht H et al. Happiness in dermatology: a holistic evaluation of the mental burden of skin diseases. J Eur Acad Dermatol Venereol. 2020; 34: 1331-9.
Augustin M, Eissing L, Langenbruch A et al. The German National Program on Psoriasis Health Care 2005-2015: results and experiences. Arch Dermatol Res 2016; 308: 389-400.
Rendon A, Schakel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci 2019; 20(6): 1475.
Nast A, Amelunxen L, Augustin M et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges 2018; 16: 645-69.
Nast A, Amelunxen L, Augustin M et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. J Dtsch Dermatol Ges 2018; 16: 806-13.
Gaskins M, Dressler C, Werner RN et al. Methods report: Update of the German S3 guideline for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2018; 16(5).
Kiedrowski R, Dirschka T, Kurzen H et al. Empfehlungen für die ambulante Versorgung von Psoriasis vulgaris - Aktualisierter praxisnaher Behandlungspfad. Der Deutsche Dermatologe 2019; 09: 1-24.
World Health Organization. Global report on psoriasis. World Health Organization, Geneva, 2016.
Schielein MC, Tizek L, Seifert F et al. Versorgung von chronisch entzündlichen Hauterkrankungen. Der Hautarzt 2019; 70: 875-82.
Schielein MC, Tizek L, Rotter M et al. Guideline-compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria. J Eur Acad Dermatol Venereol 2018; 32: 978-84.
Otani K, Waterman B, Faulkner KM et al. How patient reactions to hospital care attributes affect the evaluation of overall quality of care, willingness to recommend, and willingness to return. J Healthc Manag 2010; 55: 25-37; discussion 38.
Whooley MA, Avins AL, Miranda J et al. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12: 439-45.
Spitzer RL, Williams JB, Kroenke K et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA 1994; 272: 1749-56.
Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983-94.
Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-36.
Augustin M, Krüger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-72.
Tranos E, Stich C. Individual internet usage and the availability of online content of local interest: A multilevel approach. Comput Environ Urban Syst 2020; 79: 101371.
Dommasch ED, Shin DB, Troxel AB et al. Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. Br J Dermatol 2010; 162: 835-42.
Krueger G, Koo J, Lebwohl M et al. The Impact of Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 2001; 137: 280-4.
Langenbruch A, Radtke MA, Jacobi A et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res 2016; 308: 401-8.
Ighani A, Partridge ACR, Shear NH et al. Comparison of management guidelines for moderate-to-severe plaque psoriasis: A review of phototherapy, systemic therapies, and biologic agents. J Cutan Med Surg 2019; 23: 204-21.
Psomadakis CE, Han G. New and emerging topical therapies for psoriasis and atopic dermatitis. J Clin Aesthet Dermatol 2019; 12: 28-34.
McCabe SE, Diez A, Boyd CJ et al. Comparing web and mail responses in a mixed mode survey in college alcohol use research. Addictive behaviors 2006; 31: 1619-27.
Callas PW, Solomon LJ, Hughes JR et al. The influence of response mode on study results: offering cigarette smokers a choice of postal or online completion of a survey. J Med Internet Res 2010; 12: e46-e46.
Arafa AE, Anzengruber F, Mostafa AM et al. Perspectives of online surveys in dermatology. J Eur Acad Dermatol Venereol 2019; 33: 511-20.
Wright K. Researching internet-based populations: advantages and disadvantages of online survey research, online questionnaire authoring software packages, and web survey services. J Computer-Mediated Communication 2005; 10.
Sheikh K, George A, Gilson L. People-centred science: Strengthening the practice of health policy and systems research. Health research policy and systems /BioMed Central 2014; 12: 19.
Starfield B. Is patient-centered care the same as person-focused care? Perm J 2011; 15: 63-9.
Gruesser M, Bott U, Ellermann P et al. Evaluation of a structured treatment and teaching program for non-insulin-treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care 1993; 16: 1268-75.